Liquidia: Assessing United Therapeutics Claim and Recent Legal Victories

 As of June 29, 2023, Liquidia is currently assessing a claim made by United Therapeutics regarding their patent application known as the ‘066 patent. It is worth noting that United Therapeutics has recently emerged victorious in a legal battle concerning a patent for a dry powder inhaler. The court ruled in favor of United Therapeutics, determining that Liquidia would be guilty of inducing infringement of multiple claims from the ‘793 patent if they were to market Yutrepia. However, it is important to mention that in a previous decision, the Patent Trial and Appeal Board (PTAB) had declared all claims of the ‘793 patent to be invalid.

LQDA, also known as Liquidia Corporation, is a health technology company in the pharmaceutical industry. On June 29, 2023, the stock opened at $9.00, slightly higher than the previous day’s closing price of $8.92. Throughout the day, the stock traded within a range of $8.90 to $9.95. The trading volume was 635,525 shares, higher than the average volume of 494,963 shares over the past three months.

With a market capitalization of $581.8 million, LQDA is considered a mid-cap stock. The company’s earnings growth in the last year was positive at 3.35%, indicating a modest increase in profitability. However, the earnings growth for this year is negative at -5.76%, suggesting a decline in profitability compared to the previous year. Looking ahead, the earnings growth forecast for the next five years is -30.80%, indicating a challenging outlook for the company.

On the revenue front, LQDA experienced a growth rate of 2.76% in the last year, which suggests a moderate increase in sales. However, the company’s profitability remains a concern, as it reported an annual profit of -$41.0 million with a net profit margin of -257.39%. These figures indicate that the company is currently operating at a loss.

When evaluating a stock, investors often consider valuation metrics such as the price-to-earnings (P/E) ratio, price/sales ratio, and price/book ratio. Unfortunately, the P/E ratio for LQDA is not available (NM), making it challenging to assess the stock’s valuation based on traditional metrics. However, the price/sales ratio stands at 24.37, which suggests that investors are willing to pay a premium for each dollar of the company’s sales. The price/book ratio is 6.41, indicating that the stock is trading at a higher valuation compared to its book value.

https://beststocks.com/assessing-united-therapeutics-claim-and-recen/